Director Chetan Shah receives 21,815 RSUs at Aethlon Medical (AEMD)

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Shah Chetan reported acquisition or exercise transactions in this Form 4 filing.

Aethlon Medical director Chetan Shah received a stock-based compensation grant. He was awarded 21,815 shares of Common Stock at a reference price of $2.29 per share, classified as a grant or award, increasing his directly held stake to 23,021 shares.

The award represents RSUs that vest in four equal quarterly installments on June 30, 2026, September 30, 2026, December 31, 2026 and March 31, 2027, conditioned on his continued service with the company on each vesting date. This is a routine compensation-related equity grant rather than an open-market purchase.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Shah Chetan

Role null

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	21,815	$2.29	$50K

Holdings After Transaction: Common Stock — 23,021 shares (Direct, null)

Footnotes (1)

[object Object]

Key Figures

RSU grant size: 21,815 shares Grant reference price: $2.29 per share Post-grant holdings: 23,021 shares +2 more

5 metrics

RSU grant size 21,815 shares Grant of Common Stock RSUs to director Chetan Shah

Grant reference price $2.29 per share Reported transaction price per share for the award

Post-grant holdings 23,021 shares Common Stock directly held by Chetan Shah after transaction

Vesting start date June 30, 2026 First quarterly vesting date for granted RSUs

Final vesting date March 31, 2027 Last of four quarterly vesting dates for RSUs

Key Terms

RSUs, vest, quarterly installments, continued service

4 terms

RSUs financial

"The Reporting Person was granted RSUs that vest in four equal quarterly installments"

RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.

vest financial

"RSUs that vest in four equal quarterly installments on each of June 30, 2026, September 30, 2026, December 31, 2026 and March 31, 2027"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

quarterly installments financial

"RSUs that vest in four equal quarterly installments on each of June 30, 2026, September 30, 2026, December 31, 2026 and March 31, 2027"

continued service financial

"subject to the Reporting Person's continued service with the Company on each such vesting date"

Form 4 Insider Transactions: What Each Field Means →

04/21/2026 - 05:00 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Shah Chetan

(Last)

(First)

(Middle)

11555 SORRENTO VALLEY RD, STE 203

(Street)

SAN DIEGO

CALIFORNIA

92121

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
AETHLON MEDICAL INC [ AEMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	04/17/2026		A		21,815⁽¹⁾	A	$2.29	23,021	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. The Reporting Person was granted RSUs that vest in four equal quarterly installments on each of June 30, 2026, September 30, 2026, December 31, 2026 and March 31, 2027, subject to the Reporting Person's continued service with the Company on each such vesting date.

	/s/ Chetan Shah, by: James B. Frakes, Attorney-in-fact	04/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Aethlon Medical (AEMD) disclose about director Chetan Shah?

Aethlon Medical disclosed that director Chetan Shah received a stock-based compensation grant of 21,815 shares of Common Stock. These shares are in the form of RSUs that vest over four quarterly dates in 2026 and 2027, subject to his continued service.

How many Aethlon Medical (AEMD) shares were granted to Chetan Shah?

Chetan Shah was granted 21,815 shares of Aethlon Medical Common Stock. The grant is reported at a reference price of $2.29 per share as a compensation award, not an open-market purchase, and vests in four equal quarterly installments through March 31, 2027.

When do Chetan Shah’s AEMD RSUs vest?

The RSUs awarded to Chetan Shah vest in four equal quarterly installments. Vesting dates are June 30, 2026, September 30, 2026, December 31, 2026, and March 31, 2027, provided he continues serving the company on each vesting date.

Is Chetan Shah’s AEMD Form 4 transaction an open-market buy or a grant?

The Form 4 transaction for Chetan Shah is a grant, not an open-market purchase. It is coded as a grant or award acquisition of 21,815 RSU-based shares, awarded as director compensation and vesting over time, rather than shares bought on the open market.

What is Chetan Shah’s Aethlon Medical shareholding after this grant?

Following the reported grant, Chetan Shah directly holds 23,021 shares of Aethlon Medical Common Stock. This figure reflects his position after the 21,815-share award, according to the Form 4, and represents his direct ownership stake following the compensation-related transaction.